Blood pressure reduction in hypertensive-diabetic rats by the somatostatin analog MK-678.
A hypotensive effect of an orally-administered cyclopeptide somatostatin analog, MK-678, has been demonstrated in a hypertensive diabetic rat model. Sustained blood pressure reduction failed to occur when the drug was administered to the spontaneously hypertensive rat. The mechanism of hypotension appears independent of effects on a variety of hormones including insulin, glucagon, growth hormone, and components of the renin-angiotensin system including renin activity, plasma angiotensin converting enzyme, and aldosterone.
Hartmann
J
J
Merck Sharp & Dohme Research Laboratories, Department of Biochemical Endocrinology, Rahway, NJ 07065.
Szemplinski
M
M
Chen
S L
SL
Slater
E
E
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000503:physiopathology*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D051381:Rats; D011918:Rats, Inbred SHR; D011919:Rats, Inbred Strains; D012016:Reference Values; D013004:Somatostatin / Q000031:analogs & derivatives*; D013997:Time Factors
D001786:Blood Glucose; D010456:Peptides, Cyclic; D013004:Somatostatin; C040968:seglitide